Clinical Trials Browser

NIH × irofulven × Clear all

NCT00053365 2019-07-24

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Completed

61 enrolled 10 charts

Carcinoma, Ovarian Epithelial

NCT00012038 2013-06-24

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

Phase 1/2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00003390 2013-06-21

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00019552 2013-06-20

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00062257 2013-05-15

Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT00003796 2013-02-11

Irofulven in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00003997 2013-02-08

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00003370 2013-02-05

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific